Salima Daou
- Molecular Biology top 10%
- Ubiquitin and proteasome pathways 10
- Glycosylation and Glycoproteins Research 3
- RNA modifications and cancer 3
- Histone Deacetylase Inhibitors Research 3
- Epigenetics and DNA Methylation 3
- Protein Degradation and Inhibitors 3
- Oncology top 10%
- Peptidase Inhibition and Analysis 3
- Cancer-related Molecular Pathways 3
- Ophthalmology top 5%
- Co-authors
- El Bachir AffarIan Hammond-MartelHaithem BarbourNazar MashtalirHelen YuHelen PakElliot DrobetskyÉric Milot
- Journals
- Nature Communications (3 papers)Proceedings of the National Academy of Sciences (3 papers)Journal of Visualized Experiments (2 papers)
- Partner nations
- CanadaUnited StatesChina
In The Last Decade
Salima Daou
18 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 59
- Molecular Biology 861
- Oncology 242
- Cancer Research 122
- Ophthalmology 68
- Immunology 158
Countries citing papers authored by Salima Daou
This map shows the geographic impact of Salima Daou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Salima Daou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Salima Daou more than expected).
Fields of papers citing papers by Salima Daou
This network shows the impact of papers produced by Salima Daou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Salima Daou. The network helps show where Salima Daou may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Salima Daou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 6 | |
| 2 | 2024 | 2 | |
| 3 | 2023 | 30 | |
| 4 | 2020 | 21 | |
| 5 | 2020 | 15 | |
| 6 | 2020 | 90 | |
| 7 | 2019 | 2 | |
| 8 | 2019 | 3 | |
| 9 | 2018 | 41 | |
| 10 | 2017 | 1 | |
| 11 | 2015 | 26 | |
| 12 | 2015 | 86 | |
| 13 | 2014 | 142 | |
| 14 | 2014 | 40 | |
| 15 | 2013 | 62 | |
| 16 | 2013 | 262 | |
| 17 | 2011 | 83 | |
| 18 | 2010 | 205 |
About Salima Daou
Salima Daou is a scholar working on Molecular Biology, Oncology, Immunology, Hematology and Organic Chemistry, having authored 18 papers that have together received 1.1k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (10 papers), Glycosylation and Glycoproteins Research (3 papers), RNA modifications and cancer (3 papers), Peptidase Inhibition and Analysis (3 papers), Histone Deacetylase Inhibitors Research (3 papers), Epigenetics and DNA Methylation (3 papers), Cancer-related Molecular Pathways (3 papers) and Protein Degradation and Inhibitors (3 papers). The work is most often cited by research in Molecular Biology (861 citations), Oncology (242 citations), Cancer Research (122 citations), Ophthalmology (68 citations) and Immunology (158 citations). Salima Daou has collaborated with scholars based in Canada, United States and China. Frequent co-authors include El Bachir Affar, Ian Hammond-Martel, Haithem Barbour, Nazar Mashtalir, Helen Yu, Helen Pak, Elliot Drobetsky, Éric Milot, Guangchao Sui and Jessica K. Gagnon. Their work appears in journals such as Nature Communications, Proceedings of the National Academy of Sciences, Journal of Visualized Experiments, iScience and Molecular and Cellular Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.